[Psychopharmacologically qualified side effects with distigmine bromide therapy (UBRETID, BC 51)].
D000065:Accommodation, Ocular / Q000187:drug effects; D001002:Anuria / Q000139:chemically induced / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D004341:Drug Evaluation; D006801:Humans; D006945:Hyperhidrosis / Q000139:chemically induced / Q000188:drug therapy; D009157:Myasthenia Gravis / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy; D011619:Psychotropic Drugs / Q000009:adverse effects*; D011726:Pyridinium Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy
D011619:Psychotropic Drugs; D011726:Pyridinium Compounds
Therapie psychopharmakabedingter Nebenwirkungen mit Distigminbromid (UBRETID, BC 51)